Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

This study has been completed.
Sponsor:
Collaborator:
Endo Pharmaceuticals
Information provided by (Responsible Party):
Clinvest, Cady, Roger, M.D.
ClinicalTrials.gov Identifier:
NCT00846495
First received: February 17, 2009
Last updated: January 11, 2012
Last verified: January 2012
  Purpose

Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.


Condition Intervention Phase
Migraine
Drug: topiramate
Drug: frovatriptan
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine

Resource links provided by NLM:


Further study details as provided by Cady, Roger, M.D.:

Primary Outcome Measures:
  • Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate [ Time Frame: Treatment Month 2 ] [ Designated as safety issue: No ]
    Compare number of migraine attacks reported by participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate during Treatment Period Month 2

  • Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine [ Time Frame: Treatment Month 2 ] [ Designated as safety issue: No ]
    Measure the change in number of headache days between participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate to prevent migraine


Secondary Outcome Measures:
  • Number of Headache Days Each Month Following Initiation of Treatment With Study Medication [ Time Frame: 2 Months ] [ Designated as safety issue: No ]
    Measure the change in number of headache days reported by participants during each treatment month following initiation of treatment with study medication

  • Participants With Greater Than 50% Reduction in Migraine Attacks and Headache Days Per Month Utilizing Each Treatment Paradigm [ Time Frame: 2 Months ] [ Designated as safety issue: No ]
    Compare number of participants with greater than 50% reduction in migraine attacks and headache days from Baseline to Treatment Months 1 and 2

  • Quality of Life in Subjects Utilizing Each Treatment Paradigm [ Time Frame: Randomization, End of Treatment Month 1, End of Treatment Month 2 ] [ Designated as safety issue: No ]
    Quality of Life is measured by the Migraine Specific Quality of Life Questionnaire (MSQ), which includes 3 dimensions: Role Function Restrictive (degree to which performance of daily activities is limited), Role Function Preventive (degree to which performance of daily activities is interrupted), and Emotional Function (frustration and helplessness due to migraine). Scores range from 0 to 100. For each dimension, a higher score indicates a better health status. Participants completed the MSQ at Randomization, and after Treatment Months 1 and 2.

  • Participant Satisfaction With Study Medications [ Time Frame: Treatment Month 2 ] [ Designated as safety issue: No ]

    Participant satisfaction is measured by the Patient Perception of Migraine Questionnaire (PPMQ). Questions were categorized within 6 dimensions: Efficacy, Functionality, Ease of Use, Cost, Bothersomeness of Side Effects, and Total Score. Scores range from 0 to 100. Higher scores represent better satisfaction.

    Participants completed the PPMQ 24 hours following each first dose of frovatriptan.


  • Adverse Events Associated With Study Medications [ Time Frame: Treatment Months 1 and 2 ] [ Designated as safety issue: Yes ]
    Includes Adverse Events at or above 5% frequency per group.

  • Cost of Frovatriptan vs. Topiramate as Preventive Treatment of Migraine [ Time Frame: Treatment Months 1 and 2 ] [ Designated as safety issue: No ]
    Average cost of study medication taken by each subject. Measured in dollars.


Enrollment: 55
Study Start Date: August 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: topiramate
Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
Drug: topiramate
topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
Other Name: Topamax
Active Comparator: frovatriptan
Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
Drug: frovatriptan
frovatriptan 5mg tab during premonitory phase of migraine
Other Name: Frova

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA

  1. Subject has at least a one-year history of migraine with or without aura meeting International Headache Society criteria (see Appendix)
  2. Subject has a 3-month history of averaging 3-6 migraines per month
  3. Subject reports premonitory symptoms and the ability to predict at least 50% of high impact headaches
  4. Subjects must currently or have in the past successfully utilized a triptan as an acute treatment for migraine as determined by the investigator.
  5. Male or female at least 18 years of age
  6. Subject of childbearing potential agrees to use adequate contraception during the study. Adequate methods of contraception are to be determined by the investigator and should be consistent with contraceptive care administered in the regular clinical use of frovatriptan and topiramate.
  7. Subject is aware of prodrome symptoms that may include physiological, psychological or cognitive changes. These may include, but are not limited to such symptoms as Pre-Menstrual Syndrome (PMS), change in mood, energy level, appetite, food craving, nausea, sense of hearing, sense of smell or swelling/fluid retention, excessive yawning, head pain, muscle pain/tenderness, irritability, confusion, extreme sleepiness, impaired speech or impaired memory. (The subject should be able to differentiate these symptoms from other similar symptoms that do not precede migraine). The symptoms should precede migraine by 4-24 hours signaling an impending migraine attack.
  8. Subject is able to understand instructions for the study and complete the diary
  9. Subject is willing to give informed consent to participate in the study
  10. Any migraine prophylactic medication must have a stabilized dosage for one month

EXCLUSION CRITERIA

  1. History of any medical condition that would confound the results of the study including but not limited to the following:

    • Hepatic disease or significant hepatic dysfunction
    • History of pancreatitis
    • History of thrombocytopenia
    • History of glaucoma
    • History of osteoporosis or osteopenia
    • Cardiovascular Disease - Coronary artery disease, Ischemic heart disease or Significant Arrhythmia
    • History of active Cerebrovascular Disease
    • Hypertension - Uncontrolled hypertension in a non-migrainous state (> 160 mmHg systolic or >95 mmHg. diastolic). Hypertension must be controlled effectively with medication for a period of 3 months.
    • Basilar or Hemiplegic Migraine
    • Significant peripheral vascular disease or Raynaud's Syndrome
    • Significant Active Renal, Hepatic, Gastrointestinal, Endocrine or
    • Neurological Disease
    • History of depression, mood problems or suicidal thoughts or behavior that in the opinion of the Investigator would interfere with participation in the study.
  2. History of ergotamine, "triptan", or analgesic abuse within past 3 months
  3. History of current or recent drug or alcohol abuse that would interfere with participation in the study.
  4. More than 15 headache days per month within past 3 months.
  5. Women who are pregnant or breast feeding
  6. Subjects with known hypersensitivity or intolerance to topiramate or any triptan-like medication
  7. Subject is scheduled for surgical procedure to occur while enrolled in study.that in opinion of the Investigator would interfere with participation in the study.
  8. Subject is on a ketogenic diet
  9. Participation in another investigative drug study within the previous 30 days
  10. Excluded medications: MAO Inhibitors, lithium, methylergonovine, methysergide, ergotamine-containing products, or topiramate daily for migraine prophylaxis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00846495

Locations
United States, Florida
Physician Associates LLC
Oviedo, Florida, United States, 32765
United States, Missouri
Clinvest
Springfield, Missouri, United States, 65807
Sponsors and Collaborators
Clinvest
Endo Pharmaceuticals
Investigators
Principal Investigator: Roger K Cady, MD Clinvest
  More Information

Publications:
Responsible Party: Clinvest, CEO, Cady, Roger, M.D.
ClinicalTrials.gov Identifier: NCT00846495     History of Changes
Other Study ID Numbers: Frova vs. Topiramate
Study First Received: February 17, 2009
Results First Received: June 9, 2011
Last Updated: January 11, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Cady, Roger, M.D.:
Migraine
Migraine prevention
Prodrome
Premonitory phase
Preemptive therapy

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Topiramate
Frovatriptan
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 29, 2014